Regulatory and commercial legal for Swiss pharma and life sciences in India.
A Swiss company entering pharmaceuticals and life sciences in India operates under a defined regulatory frame: inbound investment under FEMA and the consolidated FDI policy, the activity-specific regime of the Central Drugs Standard Control Organisation (CDSCO), the Drugs and Cosmetics Act 1940 and the National Pharmaceutical Pricing Authority, and the corporate, tax, employment and data obligations common to any operating company. The sectoral rules decide the entry route, the permitted shareholding and the licences, so they must be mapped before the structure is fixed.
AMLEGALS advises Swiss investors across the pharmaceuticals and life sciences life cycle in India — entry structure and FDI route, sectoral licensing and approvals, commercial contracts, IP and data, and dispute resolution. We connect the sectoral regulation to the corporate and tax structure so the Swiss group has one coherent India position rather than disconnected advice.
Determining the entry vehicle, the automatic or government route and the sectoral cap for pharmaceuticals and life sciences.
Securing the approvals and registrations required under the Central Drugs Standard Control Organisation (CDSCO), the Drugs and Cosmetics Act 1940 and the National Pharmaceutical Pricing Authority.
Drafting the supply, distribution, manufacturing and services agreements for the pharmaceuticals and life sciences operation.
Protecting and licensing the Swiss group’s technology and brands and securing India-created IP.
Building DPDPA and ongoing regulatory compliance for the India operation.
Managing regulatory, commercial and enforcement matters arising in the pharmaceuticals and life sciences sector.
Yes, subject to the sectoral FDI position. Many activities are on the automatic route up to the applicable cap, while some require government approval or carry conditions. AMLEGALS confirms the route, cap and conditions under the consolidated FDI policy and the Central Drugs Standard Control Organisation (CDSCO), the Drugs and Cosmetics Act 1940 and the National Pharmaceutical Pricing Authority before the structure is fixed.
The licences and registrations depend on the activity and are governed by the Central Drugs Standard Control Organisation (CDSCO), the Drugs and Cosmetics Act 1940 and the National Pharmaceutical Pricing Authority. AMLEGALS identifies the full approval set at the outset so the timeline and sequence are built into the entry plan.
Most operating investments use a wholly owned subsidiary or, where an Indian partner is required, a joint venture. The choice turns on the sectoral cap, the need for local participation, control and exit. AMLEGALS structures it for both the sectoral rules and tax efficiency under the India–Switzerland DTAA.
Through the sector regulator’s mechanisms where applicable and through commercial arbitration or the commercial courts for contractual disputes. AMLEGALS drafts enforceable dispute clauses and represents the Swiss group if a dispute arises.
No. No engagement is treated as accepted until conflicts, scope and terms are confirmed in writing. An initial discussion is confidential and is used only to understand the matter and assess fit.
Share the key facts for a confidential preliminary assessment of your India matter.